Tango Therapeutics Inc (TNGX)

Currency in USD
6.64
+0.14(+2.15%)
Real-time Data·
TNGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
TNGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.506.80
52 wk Range
1.0312.02
Key Statistics
Prev. Close
6.5
Open
6.62
Day's Range
6.5-6.8
52 wk Range
1.03-12.02
Volume
1.89M
Average Volume (3m)
3.18M
1-Year Change
-27.86%
Book Value / Share
1.25
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TNGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.86
Upside
+63.51%
Members' Sentiments
Bearish
Bullish
ProTips
5 analysts have revised their earnings upwards for the upcoming period

Tango Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Tango Therapeutics Inc Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Tango Therapeutics Inc SWOT Analysis


Innovative Pipeline
Tango Therapeutics' PRMT5 inhibitor trials for pancreatic and lung cancers could revolutionize treatment, with expansion data expected in late 2025
Financial Outlook
Despite projected losses, Tango extends cash runway to Q1 2027, demonstrating efficient capital allocation and maintaining a healthy current ratio of 6.26
Market Positioning
Explore Tango's unique position in targeted cancer therapies, with recent 53% price return and analyst price target of $13, despite being 61% below 52-week high
Growth Potential
Delve into Tango's opportunities in precision oncology, including expansion into multiple cancer indications and potential partnerships with pharmaceutical giants
Read full SWOT analysis

Compare TNGX to Peers and Sector

Metrics to compare
TNGX
Peers
Sector
Relationship
P/E Ratio
−5.1x−1.1x−0.5x
PEG Ratio
0.26−0.060.00
Price/Book
5.5x2.2x2.6x
Price / LTM Sales
30.7x9.4x3.3x
Upside (Analyst Target)
53.8%312.7%43.5%
Fair Value Upside
Unlock19.2%6.9%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.86
(+63.51% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
-0.35 / -0.35
Revenue / Forecast
3.18M / 6.42M
EPS Revisions
Last 90 days

TNGX Income Statement

People Also Watch

79.01
OKLO
-4.92%
41.04
BMNR
+6.68%
9.53
PHAT
+9.79%
18.32
URGN
-8.45%
6.785
NVTS
+6.85%

FAQ

What Stock Exchange Does Tango Therapeutics Trade On?

Tango Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Tango Therapeutics?

The stock symbol for Tango Therapeutics is "TNGX."

What Is the Tango Therapeutics Market Cap?

As of today, Tango Therapeutics market cap is 735.43M.

What Is Tango Therapeutics's Earnings Per Share (TTM)?

The Tango Therapeutics EPS (TTM) is -1.32.

When Is the Next Tango Therapeutics Earnings Date?

Tango Therapeutics will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is TNGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Tango Therapeutics Stock Split?

Tango Therapeutics has split 0 times.

How Many Employees Does Tango Therapeutics Have?

Tango Therapeutics has 155 employees.

What is the current trading status of Tango Therapeutics (TNGX)?

As of 07 Aug 2025, Tango Therapeutics (TNGX) is trading at a price of 6.64, with a previous close of 6.50. The stock has fluctuated within a day range of 6.50 to 6.80, while its 52-week range spans from 1.03 to 12.02.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.